This CPB has been revised to: (i) state that brentuximab (Adcetris) is considered medically necessary in combination with nivolumab for relapsed or refractory Classical Hodgkin lymphoma (CHL); (ii) reword the continued therapy criteria; (ii) restructure existing criteria according to NCCN nomenclature; and (iii) state that brentuximab for the treatment of acute myeloid leukemia is considered experimental and investigational.